Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2326 - Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Thoracic Malignancies


Francesco Grossi


Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


F. Grossi1, L. Crinò2, A. Delmonte3, D. Turci4, G. Lo Russo5, F. De Marinis6, H.J. Soto Parra7, D. Galetta8, F. Cappuzzo9, F. Sperandi10, M. Tiseo11, G. Puppo12, F. Roila13, M.R. Migliorino14, G. Tonini15, F. Cognetti16, A. Santoro17, D. Tassinari18, A. Scoppola19, E. Cortesi20

Author affiliations

  • 1 Medical Oncology, Policlinico San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, 16132 - Genova/IT
  • 2 Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)- IRCCS, Meldola/IT
  • 3 Department Of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola/IT
  • 4 Medical Oncology, Ospedale “S.Maria delle Croci, 48400 - Ravenna/IT
  • 5 Clinical Oncology, Isituto Nazionale dei Tumori, 20133 - Milano/IT
  • 6 Oncologia, Istituto Europeo di Oncologia, Milano/IT
  • 7 Medical Oncology, AOU Policlinico Vittorio EManuele, 95123 - Catania/IT
  • 8 Medical Oncology, Istituto Tumori Giovanni Paolo II, Bari/IT
  • 9 Medical Oncology, Ospedale Civile di Ravenna - S.ta Maria delle Croci, 48121 - Ravenna/IT
  • 10 Medical Oncology, Policlinico Sant'Orsola-Malpighi, Bologna/IT
  • 11 Medical Oncology, Università degli Studi di Parma - Facoltà di Medicina e Chirurgia, 43125 - Parma/IT
  • 12 Oncology, AOU Pisana, Pisa/IT
  • 13 Medical Oncology, Azienda Ospedaliera Sta Maria, 5100 - Terni/IT
  • 14 Pulmonary Oncology Unit, Azienda Ospedaliera S. Camillo Forlanini, 152 - Roma/IT
  • 15 Medical Oncology, Campus Bio-Medico di Roma, 128 - Roma/IT
  • 16 Medical Oncology 1, Regina Elena National Cancer Institute, 00144 - Rome/IT
  • 17 Oncology And Hematology, Istituto Clinico Humanitas, Milano/IT
  • 18 8ausl Della Romagna, Rimini, USL della Romagna, Rimini, rimini/IT
  • 19 Medical Oncology, Istituto Dermopatico dell’Immacolata, Roma, Roma/IT
  • 20 Medical Oncology, Policlinico Umberto I, 161 - Roma/IT


Abstract 2326


Nivolumab monotherapy has shown survival benefit in patients (pts) with different tumors, including melanoma, lung cancer, renal cell carcinoma and head and neck cancer. The experience of pts and physicians in routine clinical practice is often different from that in a controlled clinical trial setting. Here, we report efficacy and safety of nivolumab monotherapy in pts with non-squamous non-small cell lung cancer (NSCLC) treated in the nivolumab Expanded Access Programme in Italy.


Nivolumab was available upon physician request for pts aged ≥18 years who had relapsed after a minimum of one prior systemic treatment for stage IIIB/stage IV non-Squamous NSCLC. Nivolumab 3 mg/kg was administered intravenously every 2 weeks to a maximum of 24 months. Pts included in the analysis had received at least 1 dose of nivolumab and were monitored for adverse events (AE) using Common Terminology Criteria for Adverse Events.


In total, 1588 Italian pts participated in the EAP across 168 centers. Baseline characteristics of pts were representative of the population with non-squamous NSCLC, in the advanced disease setting. With a median follow-up of 7.8 months (1-21.9) and a median of 7 doses, the overall response rate (ORR) was 18%, including 10 pts (


To date, this is the largest clinical experience with nivolumab in a real-world setting. These preliminary EAP data confirm that nivolumab seems to be an effective and safe therapy for pre-treated patients with non-squamous NCSLC, supporting its use in current clinical practice.

Clinical trial identification


Legal entity responsible for the study

Prof. Lucio Crinò


Bristol-Myers Squibb


F. Grossi: Consulting or Advisory Role: Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pierre Fabre, AstraZeneca, Roche. F. De Marinis: Consulting or Advisory Role: Bristol-Myers Squibb, AstraZeneca, Roche. H.J. Soto Parra: Consulting or Advisory Role: Bristol-Myers Squibb, Lilly. F. Cappuzzo: Consulting or Advisory Role: Bristol-Myers Squibb, Pfizer, AstraZeneca, Roche. M. Tiseo: Consulting or Advisory Role: Bristol-Myers Squibb, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Otsuka, Pierre Fabre, AstraZeneca, Novartis Pharma. M.R. Migliorino: Honoraria: Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca Consulting or Advisory Role: Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca. G. Tonini: Consulting or Advisory Role, Pierre Fabre, Molteni Farmaceutici, Novartis Pharma KK, Roche. F. Cognetti: Consulting or Advisory Role: AMtene Research Funding: Company: Genomic Health A. Scoppola: Travel, Accommodations, Expenses: IBSA. E. Cortesi: Honoraria: Janssen Corp Consulting or Advisory Role: Sirtex Medical. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.